LY2495655

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced CancerHealthy VolunteerMuscle WeaknessMuscular AtrophyPancreatic Cancer

Phase 1

A Study of LY2495655 in Healthy Subjects

CompletedNCT01341470

Eli Lilly and CompanyHealthy Volunteer

Start: 2011-05-31End: 2012-05-31Updated: 2019-06-17

A Dose-Escalation Study in Participants With Advanced Cancer

CompletedNCT01524224

Eli Lilly and CompanyAdvanced Cancer

Start: 2008-01-31End: 2016-01-31Updated: 2019-04-01

Phase 2

A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

CompletedNCT01369511

Eli Lilly and CompanyMuscular Atrophy

Start: 2011-07-31End: 2014-02-28Updated: 2018-06-06

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

CompletedNCT01505530

Eli Lilly and CompanyPancreatic Cancer

Start: 2011-12-31End: 2016-01-31Updated: 2019-09-18

A Study in Older Participants Who Have Fallen and Have Muscle Weakness

CompletedNCT01604408

Eli Lilly and CompanyMuscle Weakness

Start: 2012-05-31End: 2013-12-31Updated: 2018-04-25

Related Papers

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

2015-10-27271 citations